share_log

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K：重大事件
美股sec公告 ·  04/26 17:00
Moomoo AI 已提取核心信息
On April 23, 2024, Senti Biosciences Inc., a Delaware-incorporated biotechnology company, announced the resignation of its Chief Financial Officer, Treasurer, and Head of Corporate Development, Deborah Knobelman, Ph.D., effective May 3, 2024. Dr. Knobelman's departure is not due to any disagreements with the company's operations, policies, or practices. Following her resignation, Dr. Knobelman will enter into a consulting agreement with Senti Biosciences starting May 4, 2024, to assist with the transition of her responsibilities. She will receive a maximum payment of $60,000 for her services. Senti Biosciences is actively searching for an interim CFO and treasurer. The company plans to file the full Knobelman Consulting Agreement with its upcoming Quarterly Report on Form 10-Q for the quarter ending June 30, 2024. The report also includes forward-looking statements regarding the search for new financial leadership and acknowledges the risks and uncertainties inherent in the market and the company's SEC filings.
On April 23, 2024, Senti Biosciences Inc., a Delaware-incorporated biotechnology company, announced the resignation of its Chief Financial Officer, Treasurer, and Head of Corporate Development, Deborah Knobelman, Ph.D., effective May 3, 2024. Dr. Knobelman's departure is not due to any disagreements with the company's operations, policies, or practices. Following her resignation, Dr. Knobelman will enter into a consulting agreement with Senti Biosciences starting May 4, 2024, to assist with the transition of her responsibilities. She will receive a maximum payment of $60,000 for her services. Senti Biosciences is actively searching for an interim CFO and treasurer. The company plans to file the full Knobelman Consulting Agreement with its upcoming Quarterly Report on Form 10-Q for the quarter ending June 30, 2024. The report also includes forward-looking statements regarding the search for new financial leadership and acknowledges the risks and uncertainties inherent in the market and the company's SEC filings.
2024年4月23日，特拉华州注册成立的生物技术公司森蒂生物科学公司宣布其首席财务官、财务主管兼企业发展主管黛博拉·诺贝尔曼博士辞职，自2024年5月3日起生效。诺贝尔曼博士的离职不是由于与公司的运营、政策或做法有任何分歧。辞职后，诺贝尔曼博士将从2024年5月4日起与Senti Biosciences签订咨询协议，以协助她移交职责。她的服务最高可获得60,000美元的报酬。Senti Biosciences正在积极寻找临时首席财务官和财务主管。该公司计划在即将发布的截至2024年6月30日的季度10-Q表季度报告中提交完整的Knobelman咨询协议。该报告还包括有关寻找新的财务领导地位的前瞻性陈述，并承认了市场和公司向美国证券交易委员会提交的文件中固有的风险和不确定性。
2024年4月23日，特拉华州注册成立的生物技术公司森蒂生物科学公司宣布其首席财务官、财务主管兼企业发展主管黛博拉·诺贝尔曼博士辞职，自2024年5月3日起生效。诺贝尔曼博士的离职不是由于与公司的运营、政策或做法有任何分歧。辞职后，诺贝尔曼博士将从2024年5月4日起与Senti Biosciences签订咨询协议，以协助她移交职责。她的服务最高可获得60,000美元的报酬。Senti Biosciences正在积极寻找临时首席财务官和财务主管。该公司计划在即将发布的截至2024年6月30日的季度10-Q表季度报告中提交完整的Knobelman咨询协议。该报告还包括有关寻找新的财务领导地位的前瞻性陈述，并承认了市场和公司向美国证券交易委员会提交的文件中固有的风险和不确定性。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息